What can be learned from open direct comparative trials in multiple sclerosis?

Journal of the Neurological Sciences

Volumn 277, Issue SUPPL. 1, 2009, Pages

  Khan, Omar ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Disability; Glatiramer acetate; Interferon beta; Multiple sclerosis; Observational studies; Relapses

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO;

CLINICAL TRIAL; COMPARATIVE STUDY; DISABILITY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; POPULATION RISK; PRIORITY JOURNAL; RELAPSE;

EID: 59349104037     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(09)70008-5     Document Type: Editorial

References (18)

1. Benson K., and Hartz A.J. A comparison of observational studies and randomized, controlled trials. N Engl J Med 342 (2000) 1878-1886
2. Concato J., Shah N., and Horwitz R.I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342 (2000) 1887-1892
3. MacLehose R.R., Reeves B.C., Harvey I.M., Sheldon T.A., Russell I.T., and Black A.M. A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. Health Technol Assess (Winchester, England) 4 (2000) 1-154
4. Juni P., Altman D.G., and Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ Clin Res Ed 323 (2001) 42-46
5. Shrier I., Boivin J.F., Steele R.J., Platt R.W., Furlan A., Kakuma R., et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol 166 (2007) 1203-1209
6. Concato J. Observational versus experimental studies: what's the evidence for a hierarchy?. NeuroRx 1 (2004) 341-347
7. Cutter G., Sormani M., and Pace A. Statistical analysis of clinical endpoints in studies of disease-modifying therapies for multiple sclerosis. Neurology 70 Suppl 1 (2008) A104
8. Khan O.A., Tselis A.C., Kamholz J.A., Garbern J.Y., Lewis R.A., and Lisak R.P. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 7 (2001) 349-353
9. Carrá A., Onaha P., Sinay V., Alvarez F., Luetic G., Bettinelli R., et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing remitting multiple sclerosis. Eur J Neurol 10 (2003) 671-676
10. Haas J., and Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 12 (2005) 425-431
11. Limmroth V., Malessa R., Zettl U.K., Koehler J., Japp G., Haller P., et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing remitting multiple sclerosis. J Neurol 254 (2007) 67-77
12. Mikol D., Barkhof F., Chang P., Coyle P., Jeffery D., Musch B., et al. The REGARD trial: a randomised assessor-blinded trial comparing interferon beta-la and glatiramer acetate in relapsing remitting multiple sclerosis. Mult Scler 13 (2007) S269
13. O'Connor P., Arnason B., Comi G., Filippi M., Cook S., Goodin D., et al. Interferon beta-1b 500mcg, interferon beta-1b 250mcg and glatiramer acetate: primary outcomes of the BEYOND (Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose) study. Neurology 70 11; Late Breaking Science Supplement (2008) S004
14. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
15. Comi G., Filippi M., Wolinsky J.S., and European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 49 (2001) 290-297
16. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al., The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45 (1995) 1268-1276
17. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
18. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45 (1995) 1277-1285